Biomerica Inc. Files Q3 2025 10-Q Report

Ticker: BMRA · Form: 10-Q · Filed: Apr 14, 2025 · CIK: 73290

Biomerica INC 10-Q Filing Summary
FieldDetail
CompanyBiomerica INC (BMRA)
Form Type10-Q
Filed DateApr 14, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, diagnostics, financials

Related Tickers: BMRA

TL;DR

BIOMERICA (BMRA) filed its Q3 2025 10-Q. Check financials.

AI Summary

Biomerica Inc. filed its 10-Q for the period ending February 28, 2025. The company, previously known as NMS Pharmaceuticals Inc., is based in Irvine, CA, and operates in the in vitro & in vivo diagnostic substances sector. The filing covers the third quarter of their fiscal year, which ends on May 31st.

Why It Matters

This filing provides investors with an update on Biomerica's financial performance and operational status for the third quarter of their fiscal year, crucial for understanding the company's trajectory.

Risk Assessment

Risk Level: medium — As a diagnostic substances company, Biomerica operates in a highly regulated and competitive industry, which inherently carries medium risk.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The reporting period for this 10-Q filing is February 28, 2025.

When was this 10-Q filing submitted to the SEC?

This 10-Q filing was submitted on April 14, 2025.

What is Biomerica Inc.'s fiscal year end date?

Biomerica Inc.'s fiscal year ends on May 31st.

What industry does Biomerica Inc. operate in?

Biomerica Inc. operates in the 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' sector.

What were some of Biomerica Inc.'s previous company names?

Biomerica Inc. was formerly known as NMS Pharmaceuticals Inc., Nuclear Medical Systems Inc., and Nuclear Instruments Inc.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on April 14, 2025 regarding BIOMERICA INC (BMRA).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing